menu

A National Eye Institute Initiative—Practice Strategies to Optimize Continuity of Care for Eye Health During COVID-19

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A National Eye Institute Initiative—Practice Strategies to Optimize Continuity of Care for Eye Health During COVID-19

close
0.25 credits
15 minutes
A National Eye Institute Initiative—Practice Strategies to Optimize Continuity of Care for Eye Health During COVID-19
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Patients can suffer relapses in their visual acuity if their treatment regimen is not maintained on its defined schedule. Are you taking all necessary steps to prevent disease progression for your patients with diabetic retinopathy (DR), diabetic macular edema (DME), or neovascular age-related macular degeneration (nAMD) during the COVID-19 pandemic?

    In this discussion, Drs. Diana Shechtman and Charles Wykoff answer key questions and offer solutions related to ensuring the continuity of care for patients with these conditions during and perhaps even after the current pandemic. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Diana L. Shechtman, OD, FAAO
    Optometrist
    Retina Macular Specialists of Miami
    Miami, FL 

    Consulting Fees: Allergan, Regeneron Pharmaceuticals, Zeiss

    Faculty:
    Charles C. Wykoff, MD, PhD
    Retina Consultants of America
    Retina Consultants of Houston
    Houston Methodist Hospital & Blanton Eye Institute
    Houston, TX 

    Consulting Fees: Adverum, Aerpio, Alimera, Allegro, Allergan, Apellis, Bayer, Clearside Biomedical, DORC, EyePoint, Fosun, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, PolyPhotonix, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, Roche, Santen, Takeda
    Commercial Interest Speakers Bureau: Regeneron Pharmaceuticals
    Research Grant Support: Adverum, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Genentech, Iveric Bio (formerly Ophthotech), Kodiak, Neurotech, Novartis, Opthea, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, Roche, Samsung, Santen

    Reviewers/Content Planners/Authors:

    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose. 
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Formulate practice strategies to preserve continuity of care for patients being treated with anti-VEGF therapy for diabetic retinopathy, diabetic macular edema, or neovascular age-related macular degeneration during the COVID-19 pandemic.
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, ophthalmologic nurses, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Providers

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Patients can suffer relapses in their visual acuity if their treatment regimen is not maintained on its defined schedule. Are you taking all necessary steps to prevent disease progression for your patients with diabetic retinopathy (DR), diabetic macular edema (DME), or neovascular age-related macular degeneration (nAMD) during the COVID-19 pandemic?

    In this discussion, Drs. Diana Shechtman and Charles Wykoff answer key questions and offer solutions related to ensuring the continuity of care for patients with these conditions during and perhaps even after the current pandemic. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Diana L. Shechtman, OD, FAAO
    Optometrist
    Retina Macular Specialists of Miami
    Miami, FL 

    Consulting Fees: Allergan, Regeneron Pharmaceuticals, Zeiss

    Faculty:
    Charles C. Wykoff, MD, PhD
    Retina Consultants of America
    Retina Consultants of Houston
    Houston Methodist Hospital & Blanton Eye Institute
    Houston, TX 

    Consulting Fees: Adverum, Aerpio, Alimera, Allegro, Allergan, Apellis, Bayer, Clearside Biomedical, DORC, EyePoint, Fosun, Genentech, Kodiak, Novartis, ONL Therapeutics, Ophthotech, PolyPhotonix, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, Roche, Santen, Takeda
    Commercial Interest Speakers Bureau: Regeneron Pharmaceuticals
    Research Grant Support: Adverum, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Genentech, Iveric Bio (formerly Ophthotech), Kodiak, Neurotech, Novartis, Opthea, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, Roche, Samsung, Santen

    Reviewers/Content Planners/Authors:

    • Emily Chew, MD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose. 
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Formulate practice strategies to preserve continuity of care for patients being treated with anti-VEGF therapy for diabetic retinopathy, diabetic macular edema, or neovascular age-related macular degeneration during the COVID-19 pandemic.
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, ophthalmologic nurses, nurse practitioners, and physician assistants.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Providers

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 10/22/20